دورية أكاديمية
أعرض في EDS

Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes.

التفاصيل البيبلوغرافية
العنوان: Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes.
المؤلفون: Meister MT; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Groot Koerkamp MJA; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., de Souza T; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Breunis WB; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of Oncology and Children's Research Center, University Children's Hospital Zürich, Zürich, Switzerland., Frazer-Mendelewska E; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Brok M; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., DeMartino J; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Manders F; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Calandrini C; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Kerstens HHD; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Janse A; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Dolman MEM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Children's Cancer Institute, Lowy Cancer Centre, UNSW Sydney, Kensington, NSW, Australia.; School of Women's and Children's Health, Faculty of Medicine, UNSW Sydney, Kensington, NSW, Australia., Eising S; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Langenberg KPS; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., van Tuil M; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Knops RRG; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., van Scheltinga ST; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Hiemcke-Jiwa LS; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Flucke U; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Merks JHM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., van Noesel MM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Tops BBJ; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Hehir-Kwa JY; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Kemmeren P; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Center for Molecular Medicine, UMC Utrecht and Utrecht University, Utrecht, The Netherlands., Molenaar JJ; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., van de Wetering M; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., van Boxtel R; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Drost J; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Holstege FCP; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Center for Molecular Medicine, UMC Utrecht and Utrecht University, Utrecht, The Netherlands.
المصدر: EMBO molecular medicine [EMBO Mol Med] 2022 Oct 10; Vol. 14 (10), pp. e16001. Date of Electronic Publication: 2022 Aug 02.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: EMBO Press Country of Publication: England NLM ID: 101487380 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1757-4684 (Electronic) Linking ISSN: 17574676 NLM ISO Abbreviation: EMBO Mol Med Subsets: MEDLINE
أسماء مطبوعة: Publication: 2024- : Heidelberg : EMBO Press
Original Publication: Chichester, West Sussex : Wiley-Blackwell
مواضيع طبية MeSH: Organoids*/pathology , Rhabdomyosarcoma*/diagnosis , Rhabdomyosarcoma*/pathology, Child ; Humans
مستخلص: Rhabdomyosarcomas (RMS) are mesenchyme-derived tumors and the most common childhood soft tissue sarcomas. Treatment is intense, with a nevertheless poor prognosis for high-risk patients. Discovery of new therapies would benefit from additional preclinical models. Here, we describe the generation of a collection of 19 pediatric RMS tumor organoid (tumoroid) models (success rate of 41%) comprising all major subtypes. For aggressive tumors, tumoroid models can often be established within 4-8 weeks, indicating the feasibility of personalized drug screening. Molecular, genetic, and histological characterization show that the models closely resemble the original tumors, with genetic stability over extended culture periods of up to 6 months. Importantly, drug screening reflects established sensitivities and the models can be modified by CRISPR/Cas9 with TP53 knockout in an embryonal RMS model resulting in replicative stress drug sensitivity. Tumors of mesenchymal origin can therefore be used to generate organoid models, relevant for a variety of preclinical and clinical research questions.
(© 2022 The Authors. Published under the terms of the CC BY 4.0 license.)
References: Surgery. 1962 Oct;52:572-84. (PMID: 14484432)
Arch Med Res. 2014 Feb;45(2):143-51. (PMID: 24486246)
Lancet Oncol. 2019 Nov;20(11):1566-1575. (PMID: 31562043)
Science. 2012 Aug 17;337(6096):816-21. (PMID: 22745249)
Nat Rev Dis Primers. 2019 Jan 7;5(1):1. (PMID: 30617281)
Clin Sarcoma Res. 2012 Oct 04;2(1):14. (PMID: 23036164)
Eur J Cancer. 2008 Apr;44(6):876-84. (PMID: 18342500)
Nat Med. 2010 Feb;16(2):171-3. (PMID: 20134473)
Genome Biol. 2019 Oct 21;20(1):213. (PMID: 31639029)
Nucleic Acids Res. 2014 Dec 16;42(22):e168. (PMID: 25300484)
Nat Protoc. 2018 Feb;13(2):235-247. (PMID: 29300390)
Front Oncol. 2013 Jul 17;3:183. (PMID: 23882450)
Sci Transl Med. 2018 Jul 4;10(448):. (PMID: 29973406)
Nat Rev Cancer. 2015 Jul;15(7):426-39. (PMID: 26105539)
Stem Cell Investig. 2014 Oct 27;1:18. (PMID: 27358864)
Nature. 2009 May 14;459(7244):262-5. (PMID: 19329995)
J Exp Clin Cancer Res. 2016 Dec 5;35(1):189. (PMID: 27919280)
Nat Commun. 2020 Mar 11;11(1):1310. (PMID: 32161258)
Clin Cancer Res. 2011 Dec 1;17(23):7324-36. (PMID: 21948088)
Neuro Oncol. 2022 Apr 1;24(4):612-623. (PMID: 34850183)
J Clin Med. 2021 Apr 08;10(8):. (PMID: 33918045)
Sci Rep. 2021 Aug 17;11(1):16668. (PMID: 34404908)
J Clin Oncol. 2021 Sep 20;39(27):2979-2990. (PMID: 34343032)
J Clin Oncol. 2021 Sep 10;39(26):2859-2871. (PMID: 34166060)
Cell Rep. 2020 May 5;31(5):107588. (PMID: 32375033)
BMC Cancer. 2019 Oct 21;19(1):970. (PMID: 31638925)
Gastroenterology. 2011 Nov;141(5):1762-72. (PMID: 21889923)
Cell. 2016 Jun 16;165(7):1586-1597. (PMID: 27315476)
Nat Commun. 2019 Jul 5;10(1):2969. (PMID: 31278357)
Pediatrics. 2008 Jun;121(6):e1470-7. (PMID: 18519450)
Cell Death Dis. 2019 Feb 27;10(3):201. (PMID: 30814510)
JCO Precis Oncol. 2021 Oct 27;5:. (PMID: 34738048)
Neuro Oncol. 2021 Nov 2;23(11):1936-1948. (PMID: 34214169)
Nat Med. 2015 Nov;21(11):1318-25. (PMID: 26479923)
Cell. 2019 Jun 13;177(7):1903-1914.e14. (PMID: 31031007)
J Clin Oncol. 1999 Nov;17(11):3487-93. (PMID: 10550146)
Cell. 2021 Jun 24;184(13):3573-3587.e29. (PMID: 34062119)
Am J Pathol. 2000 Feb;156(2):399-408. (PMID: 10666368)
Cell. 2020 Jan 9;180(1):188-204.e22. (PMID: 31883794)
Cancer Cell. 2018 Jan 8;33(1):108-124.e5. (PMID: 29316425)
Am J Surg Pathol. 2019 Jun;43(6):747-754. (PMID: 30829729)
Nat Commun. 2021 Mar 3;12(1):1407. (PMID: 33658498)
Cancer Res. 1996 Jul 15;56(14):3220-4. (PMID: 8764111)
Mod Pathol. 2007 Apr;20(4):482-96. (PMID: 17334349)
Nat Methods. 2012 Jun 28;9(7):676-82. (PMID: 22743772)
Bioinformatics. 2014 Jul 15;30(14):2076-8. (PMID: 24681907)
Nature. 2017 Sep 7;549(7670):96-100. (PMID: 28854174)
Nature. 1991 Jul 25;352(6333):345-7. (PMID: 1852210)
Cell. 2015 May 7;161(4):933-45. (PMID: 25957691)
Cancer. 2019 Aug 1;125(15):2602-2609. (PMID: 31067356)
Nat Rev Drug Discov. 2015 Jun;14(6):405-23. (PMID: 25953507)
Lancet Oncol. 2018 Feb;19(2):207-215. (PMID: 29361470)
Br J Cancer. 2019 Feb;120(4):435-443. (PMID: 30745580)
Nature. 2020 Feb;578(7793):94-101. (PMID: 32025018)
Cancer Res. 2004 Aug 15;64(16):5539-45. (PMID: 15313887)
Cell. 2019 Mar 7;176(6):1282-1294.e20. (PMID: 30849372)
Nat Commun. 2020 Sep 15;11(1):4629. (PMID: 32934208)
J Surg Res. 2011 Oct;170(2):e243-51. (PMID: 21529833)
J Clin Invest. 2012 Apr;122(4):1541-52. (PMID: 22446188)
EMBO Mol Med. 2022 Oct 10;14(10):e16001. (PMID: 35916583)
Nucleic Acids Res. 2019 May 7;47(8):e47. (PMID: 30783653)
Arch Pathol Lab Med. 2015 Oct;139(10):1281-7. (PMID: 25989287)
Bioinformatics. 2011 Aug 1;27(15):2156-8. (PMID: 21653522)
Nat Protoc. 2021 Apr;16(4):1936-1965. (PMID: 33692550)
Nature. 2015 May 7;521(7550):43-7. (PMID: 25924068)
Cancer Discov. 2014 Feb;4(2):216-31. (PMID: 24436047)
Nat Rev Mol Cell Biol. 2020 Oct;21(10):571-584. (PMID: 32636524)
Life Sci Alliance. 2020 Dec 23;4(2):. (PMID: 33361335)
Clin Cancer Res. 2020 Mar 1;26(5):1135-1140. (PMID: 31699828)
Cell. 2019 May 2;177(4):821-836.e16. (PMID: 30982602)
Genome Med. 2018 Apr 25;10(1):33. (PMID: 29695279)
BMC Genomics. 2022 Feb 15;23(1):134. (PMID: 35168570)
PLoS One. 2015 Dec 30;10(12):e0146021. (PMID: 26717316)
Trends Immunol. 2020 Aug;41(8):652-664. (PMID: 32654925)
Cell Syst. 2016 Oct 26;3(4):385-394.e3. (PMID: 27693023)
Eur J Cancer. 2021 Jul;151:84-93. (PMID: 33971448)
Am J Surg Pathol. 2008 Oct;32(10):1513-22. (PMID: 18708938)
EMBO Mol Med. 2017 Feb;9(2):137-153. (PMID: 28028012)
J Biol Chem. 1998 Mar 6;273(10):5858-68. (PMID: 9488723)
EMBO J. 2019 Aug 1;38(15):e101654. (PMID: 31282586)
Cancers (Basel). 2020 Sep 18;12(9):. (PMID: 32962010)
Gigascience. 2018 Jun 1;7(6):. (PMID: 29846586)
Nature. 2012 Jan 18;481(7381):306-13. (PMID: 22258609)
Am J Clin Pathol. 1958 Apr;29(4):356-66. (PMID: 13533329)
فهرسة مساهمة: Keywords: CRISPR/Cas9; drug screening; mesenchymal; rhabdomyosarcoma; tumoroid
تواريخ الأحداث: Date Created: 20220802 Date Completed: 20221011 Latest Revision: 20230204
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9549731
DOI: 10.15252/emmm.202216001
PMID: 35916583
قاعدة البيانات: MEDLINE
الوصف
تدمد:1757-4684
DOI:10.15252/emmm.202216001